A potential new therapy for sepsis: learning from experience.
Burnham
E
E
Moss
M
M
D000818:Animals; D003422:Critical Care / Q000379:methods / Q000639:trends; D004195:Disease Models, Animal; D007166:Immunosuppressive Agents / Q000276:immunology / Q000627:therapeutic use*; D007375:Interleukin-1 / Q000037:antagonists & inhibitors* / Q000276:immunology; D011720:Pyrazoles / Q000276:immunology / Q000627:therapeutic use*; D011725:Pyridines / Q000276:immunology / Q000627:therapeutic use*; D051381:Rats; D012107:Research Design; D018805:Sepsis / Q000188:drug therapy* / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
C104334:FR 167653; D007166:Immunosuppressive Agents; D007375:Interleukin-1; D011720:Pyrazoles; D011725:Pyridines; D014409:Tumor Necrosis Factor-alpha